- EU-Mercosur FTA puts at risk access to medicines in Brazil, new impact assessment study finds
- South Centre statement on EU-MERCOSUR trade negotiations
- Hepatitis C: In Argentina INPI rejected a key patent on Sofosbuvir
- Moment of truth for global TB response
- TWN Health Info: WHO’s Study on Substandard and Falsified Medical Products: Questionable Data and Analysis
Two years ago, the European Ombudsman ruled that the European Medicines Agency should open up access to Clinical Trial Data for anyone who applied from anywhere in the world.
Six months ago two American pharmaceutical companies AbbVie and InterMune took a legal action against EMA that has closed down access to all trial data for all drugs for all doctors and researchers anywhere in the world..
Some of you may not have heard of AbbVie. Until recently they were Abbott Laboratories, one of the biggest pharmaceutical companies in the world.
They make Humira, a monoclonal antibody used for Rheumatoid Arthritis, Crohn’s Disease, Psoriasis and other conditions. It is the best selling drug in the world today, and projected to be the best selling drug of all time.
This is one of the most important legal actions in Healthcare ever. At a recent meeting in Bruxelles AbbVie made it clear that a main reason to keep clinical trial data confidential was to hide adverse event data, and perhaps even as part of a Trade War..
Sign the petition here